These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 20100660)

  • 21. Design, synthesis, and structure-activity relationship of novel and effective apixaban derivatives as FXa inhibitors containing 1,2,4-triazole/pyrrole derivatives as P2 binding element.
    Wang Y; Sun X; Yang D; Guo Z; Fan X; Nie M; Zhang F; Liu Y; Li Y; Wang Y; Gong P; Liu Y
    Bioorg Med Chem; 2016 Nov; 24(21):5646-5661. PubMed ID: 27663548
    [TBL] [Abstract][Full Text] [Related]  

  • 22. (R)-3-Amidinophenylalanine-derived inhibitors of factor Xa with a novel active-site binding mode.
    Mueller MM; Sperl S; Stürzebecher J; Bode W; Moroder L
    Biol Chem; 2002; 383(7-8):1185-91. PubMed ID: 12437104
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design and synthesis of isoxazoline derivatives as factor Xa inhibitors. 1.
    Quan ML; Liauw AY; Ellis CD; Pruitt JR; Carini DJ; Bostrom LL; Huang PP; Harrison K; Knabb RM; Thoolen MJ; Wong PC; Wexler RR
    J Med Chem; 1999 Jul; 42(15):2752-9. PubMed ID: 10425086
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preparation of 1-(4-methoxyphenyl)-1H-pyrazolo[4,3-d]pyrimidin-7(6H)-ones as potent, selective and bioavailable inhibitors of coagulation factor Xa.
    Fevig JM; Cacciola J; Buriak J; Rossi KA; Knabb RM; Luettgen JM; Wong PC; Bai SA; Wexler RR; Lam PY
    Bioorg Med Chem Lett; 2006 Jul; 16(14):3755-60. PubMed ID: 16682200
    [TBL] [Abstract][Full Text] [Related]  

  • 25. From selective substrate analogue factor Xa inhibitors to dual inhibitors of thrombin and factor Xa. Part 3.
    Dönnecke D; Schweinitz A; Stürzebecher A; Steinmetzer P; Schuster M; Stürzebecher U; Nicklisch S; Stürzebecher J; Steinmetzer T
    Bioorg Med Chem Lett; 2007 Jun; 17(12):3322-9. PubMed ID: 17462889
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cycloalkanediamine derivatives as novel blood coagulation factor Xa inhibitors.
    Nagata T; Yoshino T; Haginoya N; Yoshikawa K; Isobe Y; Furugohri T; Kanno H
    Bioorg Med Chem Lett; 2007 Aug; 17(16):4683-8. PubMed ID: 17555959
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Halothiophene benzimidazoles as P1 surrogates of inhibitors of blood coagulation factor Xa.
    Mederski WW; Dorsch D; Anzali S; Gleitz J; Cezanne B; Tsaklakidis C
    Bioorg Med Chem Lett; 2004 Jul; 14(14):3763-9. PubMed ID: 15203158
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Structural requirements for factor Xa inhibition by 3-oxybenzamides with neutral P1 substituents: combining X-ray crystallography, 3D-QSAR, and tailored scoring functions.
    Matter H; Will DW; Nazaré M; Schreuder H; Laux V; Wehner V
    J Med Chem; 2005 May; 48(9):3290-312. PubMed ID: 15857135
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The discovery of (2R,4R)-N-(4-chlorophenyl)-N- (2-fluoro-4-(2-oxopyridin-1(2H)-yl)phenyl)-4-methoxypyrrolidine-1,2-dicarboxamide (PD 0348292), an orally efficacious factor Xa inhibitor.
    Kohrt JT; Bigge CF; Bryant JW; Casimiro-Garcia A; Chi L; Cody WL; Dahring T; Dudley DA; Filipski KJ; Haarer S; Heemstra R; Janiczek N; Narasimhan L; McClanahan T; Peterson JT; Sahasrabudhe V; Schaum R; Van Huis CA; Welch KM; Zhang E; Leadley RJ; Edmunds JJ
    Chem Biol Drug Des; 2007 Aug; 70(2):100-12. PubMed ID: 17683371
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tetrahydro-isoquinoline-based factor Xa inhibitors.
    Kucznierz R; Grams F; Leinert H; Marzenell K; Engh RA; von der Saal W
    J Med Chem; 1998 Dec; 41(25):4983-94. PubMed ID: 9836616
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sulfonamidolactam inhibitors of coagulation factor Xa.
    Smallheer JM; Wang S; Laws ML; Nakajima S; Hu Z; Han W; Jacobson I; Luettgen JM; Rossi KA; Rendina AR; Knabb RM; Wexler RR; Lam PY; Quan ML
    Bioorg Med Chem Lett; 2008 Apr; 18(7):2428-33. PubMed ID: 18329876
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery of imidazo[1,5-c]imidazol-3-ones: weakly basic, orally active factor Xa inhibitors.
    Imaeda Y; Kuroita T; Sakamoto H; Kawamoto T; Tobisu M; Konishi N; Hiroe K; Kawamura M; Tanaka T; Kubo K
    J Med Chem; 2008 Jun; 51(12):3422-36. PubMed ID: 18507371
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expanding the role of coagulation in arterial thrombosis: evidence from animal models using a new factor Xa inhibitor.
    Andreotti F; Santucci E
    Thromb Haemost; 2008 Apr; 99(4):651-2. PubMed ID: 18392319
    [No Abstract]   [Full Text] [Related]  

  • 34. Molecular recognition at the active site of factor Xa: cation-π interactions, stacking on planar peptide surfaces, and replacement of structural water.
    Salonen LM; Holland MC; Kaib PS; Haap W; Benz J; Mary JL; Kuster O; Schweizer WB; Banner DW; Diederich F
    Chemistry; 2012 Jan; 18(1):213-22. PubMed ID: 22162109
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery of N-[2-[5-[Amino(imino)methyl]-2-hydroxyphenoxy]-3, 5-difluoro-6-[3-(4, 5-dihydro-1-methyl-1H-imidazol-2-yl)phenoxy]pyridin-4-yl]-N-methylgl y cine (ZK-807834): a potent, selective, and orally active inhibitor of the blood coagulation enzyme factor Xa.
    Phillips GB; Buckman BO; Davey DD; Eagen KA; Guilford WJ; Hinchman J; Ho E; Koovakkat S; Liang A; Light DR; Mohan R; Ng HP; Post JM; Shaw KJ; Smith D; Subramanyam B; Sullivan ME; Trinh L; Vergona R; Walters J; White K; Whitlow M; Wu S; Xu W; Morrissey MM
    J Med Chem; 1998 Sep; 41(19):3557-62. PubMed ID: 9733480
    [No Abstract]   [Full Text] [Related]  

  • 36. Investigation of factor Xa inhibitors containing non-amidine S1 elements.
    Franciskovich JB; Masters JJ; Tinsley JM; Craft TJ; Froelich LL; Gifford-Moore DS; Klimkowski VJ; Smallwood JK; Smith GF; Smith T; Towner RR; Weir LC; Wiley MR
    Bioorg Med Chem Lett; 2005 Nov; 15(21):4838-41. PubMed ID: 16140530
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rational design, synthesis, and structure-activity relationships of novel factor Xa inhibitors: (2-substituted-4-amidinophenyl)pyruvic and -propionic acids.
    Sagi K; Nakagawa T; Yamanashi M; Makino S; Takahashi M; Takayanagi M; Takenaka K; Suzuki N; Oono S; Kataoka N; Ishikawa K; Shima S; Fukuda Y; Kayahara T; Takehana S; Shima Y; Tashiro K; Yamamoto H; Yoshimoto R; Iwata S; Tsuji T; Sakurai K; Shoji M
    J Med Chem; 2003 May; 46(10):1845-57. PubMed ID: 12723948
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthesis of celecoxib analogs that possess a N-hydroxypyrid-2(1H)one 5-lipoxygenase pharmacophore: biological evaluation as dual inhibitors of cyclooxygenases and 5-lipoxygenase with anti-inflammatory activity.
    Chowdhury MA; Abdellatif KR; Dong Y; Das D; Suresh MR; Knaus EE
    Bioorg Med Chem Lett; 2008 Dec; 18(23):6138-41. PubMed ID: 18945614
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pyrazole-based cathepsin S inhibitors with arylalkynes as P1 binding elements.
    Ameriks MK; Axe FU; Bembenek SD; Edwards JP; Gu Y; Karlsson L; Randal M; Sun S; Thurmond RL; Zhu J
    Bioorg Med Chem Lett; 2009 Nov; 19(21):6131-4. PubMed ID: 19773165
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of ring-fused pyrazolo pyridin-2-ones as novel poly(ADP-ribose)polymerase-1 inhibitors.
    Moree WJ; Goldman P; Demaggio AJ; Christenson E; Herendeen D; Eksterowicz J; Kesicki EA; McElligott DL; Beaton G
    Bioorg Med Chem Lett; 2008 Sep; 18(18):5126-9. PubMed ID: 18713665
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.